November 9th, 2026FDA Flashback: Hematologic Cancer Decisions and News From October 2026Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.Read more
November 18th, 2026Galinpepimut-S Improves OS in AML in Second or Later RemissionMaintenance galinpepimut-S extended overall survival in transplant-ineligible AML in second or later remission.Read more
November 17th, 2026FDA Accepts sNDA for Selinexor Plus Ruxolitinib in MyelofibrosisThe FDA accepted an sNDA for selinexor plus ruxolitinib in myelofibrosis, with a target action date of June 28, 2027.Read more
November 10th, 2026Prizlon-Cel Nets FDA RMAT and Fast Track Designations in R/R LBCLThe anti-CD19/CD20 CAR T-cell therapy will be studied in the phase 2 ABZT-121 trial after progression on commercial CAR T-cell therapy.Read more